Lipocine Inc. (NASDAQ:LPCN) Stock Short Interest Jumps 259.3%

28 Oct 2026, 20:41 by Doug Wharley · The Cerbat Gem

Lipocine Inc. (NASDAQ:LPCN – Get Free Report) saw a large growth in short interest in the month of October. As of October 15th, there was short interest totaling 351,433 shares, a growth of 259.3% from the September 30th total of 97,816 shares. Based on an average daily volume of 9,616,895 shares, the short-interest ratio is currently 0.0 days. Approximately 4.5% of the shares of the company are sold short.

Wall Street Analysts Forecast Growth

LPCN has been the topic of a number of recent analyst reports. Weiss Ratings lowered Lipocine from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, October 9th. HC Wainwright reissued a “neutral” rating and issued a $4.00 target price on shares of Lipocine in a report on Monday, September 21st. Wall Street Zen raised Lipocine from a “sell” rating to a “hold” rating in a report on Saturday, July 18th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Lipocine in a research report on Tuesday, September 22nd. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $4.00.

Read Our Latest Research Report on Lipocine

Insider Activity

In other Lipocine news, Director John Higuchi bought 15,970 shares of the business’s stock in a transaction dated Wednesday, September 30th. The stock was acquired at an average cost of $2.23 per share, with a total value of $35,613.10. Following the purchase, the director owned 241,365 shares in the company, valued at approximately $538,243.95. This represents a 7.09% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Over the last ninety days, insiders purchased 37,568 shares of company stock worth $82,174. Corporate insiders own 4.69% of the company’s stock.

Institutional Investors Weigh In On Lipocine

A number of institutional investors have recently added to or reduced their stakes in LPCN. Eversept Partners LP purchased a new position in shares of Lipocine in the 1st quarter valued at $2,357,000. AIGH Capital Management LLC acquired a new position in shares of Lipocine during the 1st quarter valued at $1,598,000. Stempoint Capital LP purchased a new stake in Lipocine during the 1st quarter worth $1,282,000. Seven Fleet Capital Management LP purchased a new stake in Lipocine during the 1st quarter worth $998,000. Finally, Exome Asset Management LLC purchased a new stake in Lipocine during the 1st quarter worth $486,000. Hedge funds and other institutional investors own 9.11% of the company’s stock.

Lipocine Stock Performance

Lipocine stock traded up $0.05 during midday trading on Wednesday, reaching $1.51. 194,585 shares of the company were exchanged, compared to its average volume of 717,850. The firm’s 50-day simple moving average is $2.01 and its 200-day simple moving average is $4.07. Lipocine has a 1 year low of $1.40 and a 1 year high of $12.37. The company has a market capitalization of $12.45 million, a price-to-earnings ratio of -0.85 and a beta of 0.40.

Lipocine (NASDAQ:LPCN – Get Free Report) last announced its earnings results on Tuesday, August 4th. The specialty pharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.08. Lipocine had a negative net margin of 755.39% and a negative return on equity of 64.75%. The firm had revenue of $0.19 million for the quarter, compared to analyst estimates of $0.21 million. On average, analysts forecast that Lipocine will post -1.54 EPS for the current fiscal year.

About Lipocine

(Get Free Report)

Lipocine Inc is a biopharmaceutical company focused on developing oral therapies for conditions with significant unmet medical needs. The company uses its proprietary Lip’ral drug-delivery technology to improve the absorption and clinical performance of active pharmaceutical ingredients that may otherwise have limited effectiveness when taken orally.